MA32797B1 - Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one - Google Patents

Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one

Info

Publication number
MA32797B1
MA32797B1 MA33846A MA33846A MA32797B1 MA 32797 B1 MA32797 B1 MA 32797B1 MA 33846 A MA33846 A MA 33846A MA 33846 A MA33846 A MA 33846A MA 32797 B1 MA32797 B1 MA 32797B1
Authority
MA
Morocco
Prior art keywords
propylimino
thiazolidin
benz
ylidene
tolyl
Prior art date
Application number
MA33846A
Other languages
Arabic (ar)
English (en)
Inventor
Nicholas Bonham
Stephan Buchmann
Alex Eberlin
Christoph Imboden
Raumer Markus Von
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40097688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32797(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA32797B1 publication Critical patent/MA32797B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Abstract

LA PRÉSENTE INVENTION CONCERNE DES FORMES CRISTALLINES DE LA (R)-5[3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)- BENZ-[Z]-YLIDÈNE]-2-([Z]-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE, DES PROCÉDÉS POUR LEUR PRÉPARATION, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITES FORMES CRISTALLINES, ET LEUR UTILISATION COMME COMPOSÉS AMÉLIORANT LA FONCTION VASCULAIRE ET COMME AGENTS IMMUNOMODULATEURS, SOIT SEULS, SOIT EN ASSOCIATION AVEC D'AUTRES COMPOSÉS ACTIFS OU THÉRAPIES.
MA33846A 2008-10-20 2011-05-13 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one MA32797B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819182.7A GB0819182D0 (en) 2008-10-20 2008-10-20 Crystalline forms
PCT/IB2009/054592 WO2010046835A1 (fr) 2008-10-20 2009-10-19 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl-thiazolidin-4-one

Publications (1)

Publication Number Publication Date
MA32797B1 true MA32797B1 (fr) 2011-11-01

Family

ID=40097688

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33846A MA32797B1 (fr) 2008-10-20 2011-05-13 Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one

Country Status (28)

Country Link
US (1) US9062014B2 (fr)
EP (1) EP2344465B1 (fr)
JP (1) JP5008777B2 (fr)
KR (1) KR101409597B1 (fr)
CN (1) CN102177144B (fr)
AR (1) AR073904A1 (fr)
AU (1) AU2009305980C1 (fr)
BR (1) BRPI0919673B1 (fr)
CA (1) CA2740313C (fr)
CL (1) CL2011000867A1 (fr)
CY (1) CY1116118T1 (fr)
DK (1) DK2344465T3 (fr)
ES (1) ES2534333T3 (fr)
GB (1) GB0819182D0 (fr)
HK (1) HK1159624A1 (fr)
HR (1) HRP20150391T1 (fr)
IL (1) IL212351A (fr)
MA (1) MA32797B1 (fr)
MX (1) MX2011003988A (fr)
MY (1) MY160703A (fr)
NZ (1) NZ592854A (fr)
PL (1) PL2344465T3 (fr)
PT (1) PT2344465E (fr)
RU (1) RU2519548C2 (fr)
SI (1) SI2344465T1 (fr)
TW (1) TWI462911B (fr)
WO (1) WO2010046835A1 (fr)
ZA (1) ZA201103691B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004029493D1 (de) 2003-11-21 2010-11-18 Actelion Pharmaceuticals Ltd 5-(benz- (z) -yliden) -thiazolidin-4-onderivate als das immunsystem unterdrückende mittel
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
EP2094676B1 (fr) * 2006-11-23 2013-04-10 Actelion Pharmaceuticals Ltd. Nouveau procédé de préparation de dérivés de 2-iminothiazolidin-4-one
CA2716448A1 (fr) * 2008-03-17 2009-09-24 Patrick Brossard Regime de dosage pour un agoniste selectif du recepteur s1p<sb>1</sb>
US9238621B2 (en) * 2011-06-02 2016-01-19 Chinoin Zrt Processes for the preparation of prostaglandin amides
SI2885266T1 (sl) 2012-08-17 2020-10-30 Actelion Pharmaceuticals Ltd Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina
KR102590068B1 (ko) 2014-12-11 2023-10-16 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
MX2018007887A (es) * 2015-12-25 2019-02-20 Crystal Pharmatech Co Ltd Formas cristalinas de modulador selectivo del receptor s1p1 y método de preparación del mismo.
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11220488B2 (en) 2017-09-19 2022-01-11 Teva Pharmaceuticals International Gmbh Crystalline polymorph of Ponesimod
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
AU2020316640A1 (en) 2019-07-22 2022-03-03 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
TW202131921A (zh) 2019-10-31 2021-09-01 瑞士商愛杜西亞製藥有限公司 Cxcr7拮抗劑與s1p1受體調節劑之組合
WO2021143414A1 (fr) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 Forme cristalline de ponesimod, son procédé de préparation et son utilisation
AU2021232637A1 (en) 2020-03-06 2022-09-22 Actelion Pharmaceuticals Ltd Methods of slowing brain volume loss
WO2023022896A1 (fr) 2021-08-17 2023-02-23 Teva Czech Industries S.R.O Polymorphes de ponésimod
US20230113378A1 (en) 2021-10-11 2023-04-13 Actelion Pharmaceuticals Ltd Methods Of Treating Multiple Sclerosis
US11951097B2 (en) 2021-10-11 2024-04-09 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis
WO2023061939A1 (fr) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Méthodes de traitement de la sclérose en plaques
CA3220684A1 (fr) 2021-10-11 2023-04-20 Actelion Pharmaceuticals Ltd Methodes de traitement de la sclerose en plaques
CA3220549A1 (fr) 2021-11-05 2023-05-11 Allitia DIBERNARDO Methodes de traitement de la sclerose en plaques
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p
WO2023152290A1 (fr) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Méthodes de ralentissement d'une augmentation du volume ventriculaire cérébral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79793C2 (en) * 2002-07-10 2007-07-25 Applied Research Systems Azolidinone-vinyl fused-benzene derivatives
EP1667791A1 (fr) * 2003-10-06 2006-06-14 Solvias AG Procede pour la detection en parallele des formes cristallines de solides moleculaires
DE602004029493D1 (de) 2003-11-21 2010-11-18 Actelion Pharmaceuticals Ltd 5-(benz- (z) -yliden) -thiazolidin-4-onderivate als das immunsystem unterdrückende mittel
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
EP2094676B1 (fr) 2006-11-23 2013-04-10 Actelion Pharmaceuticals Ltd. Nouveau procédé de préparation de dérivés de 2-iminothiazolidin-4-one
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
CA2716448A1 (fr) 2008-03-17 2009-09-24 Patrick Brossard Regime de dosage pour un agoniste selectif du recepteur s1p<sb>1</sb>

Also Published As

Publication number Publication date
EP2344465A1 (fr) 2011-07-20
HK1159624A1 (en) 2012-08-03
AU2009305980C1 (en) 2015-01-22
RU2519548C2 (ru) 2014-06-10
AU2009305980B2 (en) 2014-10-02
AR073904A1 (es) 2010-12-09
IL212351A (en) 2015-09-24
SI2344465T1 (sl) 2015-04-30
PT2344465E (pt) 2015-04-23
TWI462911B (zh) 2014-12-01
PL2344465T3 (pl) 2015-06-30
MX2011003988A (es) 2011-05-10
KR101409597B1 (ko) 2014-06-20
ES2534333T3 (es) 2015-04-21
MY160703A (en) 2017-03-15
US20110196004A1 (en) 2011-08-11
CN102177144B (zh) 2014-12-31
CA2740313A1 (fr) 2010-04-29
IL212351A0 (en) 2011-06-30
EP2344465B1 (fr) 2015-01-07
RU2011119898A (ru) 2012-11-27
NZ592854A (en) 2013-01-25
AU2009305980A1 (en) 2010-04-29
KR20110071133A (ko) 2011-06-28
GB0819182D0 (en) 2008-11-26
CL2011000867A1 (es) 2011-09-23
WO2010046835A1 (fr) 2010-04-29
HRP20150391T1 (hr) 2015-05-22
CY1116118T1 (el) 2017-02-08
US9062014B2 (en) 2015-06-23
JP5008777B2 (ja) 2012-08-22
TW201022220A (en) 2010-06-16
BRPI0919673B1 (pt) 2022-02-08
CN102177144A (zh) 2011-09-07
BRPI0919673A2 (pt) 2020-09-15
JP2012505873A (ja) 2012-03-08
DK2344465T3 (en) 2015-02-16
CA2740313C (fr) 2016-09-27
ZA201103691B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
MA32797B1 (fr) Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
CL2014000270A1 (es) Compuestos derivados de 3,5-difenil diazoles sustituidos, inhibidores de la agregacion de proteinas. (divisional de la solicitud n° 1369-2010).
EA201000642A1 (ru) 2&#39;-фтор-2&#39;-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
CR20120295A (es) Triazolopiridinas
EA201171293A1 (ru) 3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
BRPI0912928A2 (pt) &#34;composto, e, composição isenta de pirogênio&#34;
EA201070853A1 (ru) Кристаллический (r)-2-(4-циклопропансульфонилфенил)-n-пиразин-2-ил-3-(тетрагидропиран-4-ил)пропионамид
UY31688A1 (es) Plaguicidas
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
SE0800742L (sv) Vikttäcke
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
MX2010006636A (es) Uso de derivados de acido tetramico para controlar nematodos.
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso
CL2007003066A1 (es) Metodo de obtencion de derivados de 8-fenil-cromanos por reduccion de la correspondiente amida.
ITMI20061848A1 (it) Procedimento per la preparazione di composti feniltetrazolici